2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial - Kellokumpu-Lehtinen, P L; Harmenberg, U; Joensuu, T (Lancet Oncol, 2013)
et al.